Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genetic abnormalities in GBM brain tumors

ABSTRACT: Examine the genetic abnormality in brain tumors

ORGANISM(S): Homo sapiens

PROVIDER: GSE24446 | GEO | 2010/11/21

SECONDARY ACCESSION(S): PRJNA133495

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Genetic abnormalities in GBM brain tumors

Project description:Examine the genetic abnormality in brain tumors Genomic DNA were extracted from frozen brain tumor samples and CGH assay were performed to compare the similarity genomic abnormality among different cell groups.

2010-11-21 | E-GEOD-24446 | biostudies-arrayexpress

Genetic abnormalities in various cell subpopulations of GBM brain tumors

Project description:GBM is a heterogenous tumor. Based on membrane protein expression, the GBM single cell dissociates were seperated into different subfractions by FACS assay. The genomic aberration among each populations were compared by analysis of CGH data. Genomic DNA were extracted from sorted cell population and CGH assay were performed to compare the similarity genomic abnormality among different cell groups.

2010-11-21 | E-GEOD-24452 | biostudies-arrayexpress

GBM brain tumors

Project description:This SuperSeries is composed of the following subset Series: GSE24446: Genetic abnormalities in GBM brain tumors GSE24452: Genetic abnormalities in various cell subpopulations of GBM brain tumors GSE24557: Exon-level expression profiles of GBM brain tumors Refer to individual Series

2010-11-21 | E-GEOD-24558 | biostudies-arrayexpress

Genetic abnormalities in various cell subpopulations of GBM brain tumors

2010-11-21 | GSE24452 | GEO

Analysis of clinicopathologic characteristics, carcinogenic mechanisms and genetic abnormality in colorectal tumors with MSI including Lynch syndrome.

Project description:Primary outcome(s): Clinicopathologic characteristics, carcinogenic mechanisms and genetic abnormality in colorectal tumors with MSI including Lynch syndrome.

| 2640382 | ecrin-mdr-crc

Immunogenomics of Malignant Brain Tumors

Project description:Immunogenomics of Malignant Brain Tumors

| PRJNA763970 | ENA

Immunogenomics of Malignant Brain Tumors

Project description:Immunogenomics of Malignant Brain Tumors

| PRJNA763945 | ENA

Exon-level expression profiles of GBM brain tumors

Project description:Transcriptome analysis of RNAs from brain tumor Investigate potential of true exon level expression profiling . We analyzed brain tumor from 16 patients (9 males, 7 females) using the Affymetrix Human Exon 1.0 ST V2 platform. Array data was processed by Affymetrix Exon Array Computational Tool.

2010-11-21 | E-GEOD-24557 | biostudies-arrayexpress

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Project description:This phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and aggressive), diffuse intrinsic pontine gliomas (brain stem tumors), brain tumors with a high number of genetic mutations, ependymoma or medulloblastoma that have come back (recurrent), progressed, or have not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may induce changes in the body’s immune system, and may interfere with the ability of tumor cells to grow and spread.

| 2183538 | ecrin-mdr-crc

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Project description:This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients’ tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor’s particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

| 2191620 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data